Ruboxistaurin is a macrocyclic bisindolylmaleimide compound under development by Eli Lilly with potential as a therapy for diabetic macular oedema and other diabetic angiopathies, including diabetic retinopathy, diabetic peripheral neuropathy and diabetic. It is an investigational drug. Reference standards of Ruboxistaurin API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
No Data Found
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
